Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study

Table 4 Adjusted hazard ratio of clinical outcomes after radiotherapy in various subtypes of breast cancer

Subtype	LR		RR		DM		DFS		OS
Subtype	aHR	95% CI	aHR	95% CI	aHR	95% CI	aHR	95% CI	aHR	95% CI
Luminal A	0.18***	0.09–0.34	0.15**	0.05–0.42	0.59	0.34–1.01	0.29***	0.20–0.42	0.62**	0.45–0.85
Luminal B/HER2-	0.22	0.03–1.80	0.06**	0.01–0.50	0.89	0.34–2.30	0.46*	0.23–0.92	0.30***	0.17–0.54
Luminal B/HER2+	0.24**	0.09–0.65	0.14*	0.03–0.63	0.68	0.36–1.27	0.38***	0.24–0.62	0.71	0.45–1.11
Basal-like	0.21	0.03–1.61	0.23	0.04–1.37	1.13	0.45–2.81	0.65	0.32–1.28	0.40***	0.25–0.63
HER2-enriched	0.79	0.30–2.14	0.90	0.12–6.50	0.74	0.29–1.92	0.85	0.47–1.54	0.50*	0.26–0.97

LR local recurrence; RR regional recurrence; DM distant metastasis; DFS disease-free survival; OS overall survival; aHR adjusted hazard ratio
aHR was obtained from multivariate analysis based on Fine and Gray competing risks proportional hazards regression model by adjusting age, clinical and pathological stage, comorbidities, chemotherapy, hormone therapy, target therapy, anti-cancer agents, and socioeconomic status
*p < 0.05; **p < 0.01; ***p < 0.0001

ISSN: 1465-542X